Lewy Body Dementia

Lewy body dementia is an umbrella term for two closely related conditions caused by the same brain pathology: dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Both result from the buildup of misfolded alpha-synuclein protein inside neurons, forming the cytoplasmic inclusions known as Lewy bodies. They differ in the order in which symptoms appear rather than in their underlying biology. When cognitive decline begins before or within one year of motor symptoms, the diagnosis is DLB; when dementia develops more than a year after established Parkinson's disease, it is PDD.

Lewy body dementia is the second or third most common neurodegenerative dementia and is frequently misdiagnosed — often as Alzheimer's disease, a primary psychiatric disorder, or simply "aging." The distinct combination of fluctuating cognition, recurrent visual hallucinations, parkinsonism, and REM sleep behavior disorder is recognizable when looked for, and the diagnosis carries important implications for medication choice, prognosis, and family support.

Understanding Lewy Body Dementia

A Synucleinopathy

Lewy body dementia belongs to the family of synucleinopathies, in which the protein alpha-synuclein misfolds and aggregates inside neurons. The same protein is implicated in Parkinson's disease and in multiple system atrophy, although the distribution of pathology differs across these conditions. In Lewy body dementia, alpha-synuclein deposits accumulate widely in the brainstem, limbic system, and neocortex, disrupting neurotransmitter systems including dopamine, acetylcholine, serotonin, and norepinephrine.

Why Cognition Fluctuates

One of the most distinctive features of Lewy body dementia is striking fluctuation in alertness, attention, and cognitive performance. A patient may seem clear, lucid, and conversational at breakfast, then nearly unresponsive or grossly confused by midafternoon, with no acute medical trigger. These fluctuations are thought to reflect dysfunction in the brainstem arousal systems and cholinergic networks that regulate attention. They are not deliberate, not psychological, and not always provoked by external factors, although they can be worsened by infection, medications, or sleep loss.

The Hallucinations Are Real Experiences

Recurrent, well-formed visual hallucinations occur in around 80 percent of people with DLB and a substantial proportion with PDD. They are typically of people, children, or animals; often non-threatening; and may be experienced with retained insight in early disease. They reflect dysfunction in visual association areas and cholinergic deficits rather than primary psychiatric illness, and they should not be reflexively treated with antipsychotics.

REM Sleep Behavior Disorder as Prodrome

REM sleep behavior disorder (RBD) is the loss of normal muscle paralysis during REM sleep, allowing people to act out their dreams — kicking, punching, shouting, or even leaping from bed. Idiopathic RBD is now recognized as the single strongest known prodrome of synucleinopathy. The majority of older adults with confirmed idiopathic RBD eventually develop Parkinson's disease, DLB, or multiple system atrophy, often a decade or more after the sleep behavior began. Identifying RBD provides a critical opportunity to monitor for early neurological signs and to plan ahead. See our page on REM sleep behavior disorder for a detailed discussion.

Frequent Misdiagnosis

Because hallucinations and fluctuations can dominate the early picture, Lewy body dementia is often mistaken for late-onset psychosis, delirium, or a primary psychiatric condition. When memory is the most reported symptom, the diagnosis may be assumed to be Alzheimer's. When parkinsonism is present but mild, it may be missed in routine evaluations. Average time from first symptoms to correct diagnosis can exceed a year and a half, and patients are frequently prescribed antipsychotics during this gap with serious consequences.

Who Develops Lewy Body Dementia

• Adults usually in their 60s, 70s, or 80s, with median onset around the early 70s
• More common in men than women, particularly for DLB
• People with longstanding REM sleep behavior disorder
• First-degree relatives have a modestly increased risk
• People with established Parkinson's disease, in whom dementia eventually develops in many cases

DSM-5 Diagnostic Criteria

DSM-5-TR recognizes Major or Mild Neurocognitive Disorder With Lewy Bodies, with criteria that closely follow the international consensus criteria for DLB published by Ian McKeith and colleagues (most recently revised in 2017). The diagnostic framework distinguishes core features, suggestive features, and supportive biomarkers.

Core Cognitive Criteria

Cognitive decline meeting the threshold for Major or Mild NCD must be present. The pattern is typically one of impaired attention and executive function with prominent visuospatial difficulty. Memory may be relatively preserved in early disease compared with Alzheimer's, although it becomes affected as the condition progresses.

Core Clinical Features

• Fluctuating cognition with pronounced variations in attention and alertness
• Recurrent visual hallucinations, typically well-formed and detailed
• REM sleep behavior disorder, which may precede other features by years
• Spontaneous parkinsonism beginning after or with cognitive symptoms

Suggestive Features

• Severe sensitivity to antipsychotic medications
• Autonomic dysfunction — orthostatic hypotension, constipation, urinary symptoms
• Hypersomnia and excessive daytime sleepiness
• Hyposmia (reduced sense of smell)
• Other psychiatric features — depression, anxiety, delusions
• Repeated falls and syncope

Biomarkers

• Reduced dopamine transporter uptake on DaT scan SPECT or PET
• Abnormal cardiac MIBG scintigraphy
• Polysomnographic confirmation of REM sleep without atonia
• Skin biopsy showing phosphorylated alpha-synuclein
• Relative preservation of medial temporal lobe structures on MRI

Probable vs. Possible DLB

Probable DLB is diagnosed when two or more core clinical features are present, or one core feature plus one or more indicative biomarkers. Possible DLB is diagnosed when only one core feature is present without supportive biomarkers, or one or more indicative biomarkers in the absence of core features.

The One-Year Rule

The boundary between DLB and PDD is based on timing. If dementia begins before or within one year of motor parkinsonism, the diagnosis is DLB. If parkinsonism is established for more than one year before dementia emerges, the diagnosis is PDD. Despite this arbitrary cutoff, the underlying biology is the same continuous synucleinopathy.

DLB and PDD: Two Faces of One Pathology

Dementia With Lewy Bodies (DLB)

In DLB, cognitive and psychiatric symptoms dominate from the start. Fluctuating attention, complex visual hallucinations, and visuospatial disorientation appear first; parkinsonism may be subtle, sometimes limited to mild rigidity, slowness, or stooped posture without prominent tremor. Patients are often referred initially to neurology for cognitive evaluation, or to psychiatry for hallucinations.

Parkinson's Disease Dementia (PDD)

In PDD, the disease starts in the typical Parkinson's pattern — resting tremor, rigidity, bradykinesia, postural instability — and progresses for years before dementia develops. Once cognitive decline appears, it follows a profile broadly similar to DLB, with executive and visuospatial impairment, fluctuations, and often hallucinations, though hallucinations may also be triggered or worsened by dopaminergic medications used to treat motor symptoms.

Multiple System Atrophy and Other Synucleinopathies

Multiple system atrophy (MSA) is a related but distinct synucleinopathy with prominent autonomic failure and either cerebellar or parkinsonian features. Dementia is less common in MSA than in DLB or PDD. Pure autonomic failure is another related condition that may evolve into one of the broader synucleinopathies over time.

Mixed Pathology

Lewy body pathology coexists with Alzheimer's pathology in a large proportion of older patients. When amyloid and tau are also present, cognitive decline tends to be faster and the clinical picture more difficult to characterize. Mixed disease is the rule in autopsy series of older adults with dementia.

Prodromal DLB

Recent diagnostic frameworks recognize a prodromal stage of DLB, in which mild cognitive impairment is accompanied by features such as RBD, autonomic dysfunction, hyposmia, or visual hallucinations. Capturing patients at this stage may allow earlier intervention as disease-modifying therapies for synucleinopathies are developed.

Symptoms and Warning Signs

Cognitive Symptoms

• Marked fluctuations in attention and alertness — "good days and bad days," sometimes hour to hour
• Visuospatial difficulty — getting lost, trouble copying figures, misjudging distances
• Slowed processing speed and executive dysfunction
• Memory difficulty that is more about retrieval than encoding in early disease
• Episodes of staring, transient unresponsiveness, or apparent absence of attention

Visual Hallucinations and Other Perceptual Phenomena

• Vivid, detailed visions of people or animals, often silent and non-threatening
• Passage hallucinations — fleeting figures in peripheral vision
• Sense of presence — the conviction that someone is nearby when no one is there
• Visual illusions — mistaking objects for people or animals
• Capgras syndrome — a delusional belief that a family member has been replaced by an impostor
• Auditory and tactile hallucinations less common but possible

Motor and Parkinsonian Features

• Bradykinesia (slowness of movement)
• Rigidity, often symmetric and axial
• Postural instability and falls
• Shuffling, narrow-based gait
• Reduced facial expression (hypomimia)
• Soft, monotone speech
• Tremor less prominent than in idiopathic Parkinson's disease

Sleep Symptoms

• REM sleep behavior disorder — dream enactment, often with vocalizations and physical movements
• Excessive daytime sleepiness, sometimes profound
• Restless legs and periodic limb movements
• Insomnia and fragmented nighttime sleep

Autonomic Symptoms

• Orthostatic hypotension — lightheadedness or falls on standing
• Constipation, often present years before other symptoms
• Urinary urgency and frequency
• Sexual dysfunction
• Excessive sweating or temperature dysregulation
• Hyposmia or anosmia

Psychiatric and Behavioral Symptoms

• Depression, often appearing before cognitive symptoms
• Anxiety and panic attacks
• Apathy and reduced initiative
• Delusions, including paranoid and Capgras-type
• Agitation, particularly in late afternoon or evening

Causes and Risk Factors

The Alpha-Synuclein Story

Alpha-synuclein is a small protein normally found at synapses. In Lewy body dementia and related synucleinopathies, the protein misfolds and aggregates inside neurons, forming Lewy bodies. The aggregates appear to spread in a stereotyped pattern through interconnected brain regions, suggesting a prion-like mechanism in which misfolded protein can template further misfolding in neighboring cells. Why this process begins in any one individual remains incompletely understood.

Genetic Factors

Most Lewy body dementia is sporadic, but several genetic factors raise risk:

• SNCA gene mutations or duplications/triplications (the gene encoding alpha-synuclein) — rare but informative
• GBA gene variants (the gene mutated in Gaucher disease) — increase risk of both Parkinson's disease and DLB
• APOE ε4 — shares an Alzheimer's risk role and is associated with both pure DLB and mixed pathology
• Family history of Parkinson's disease or dementia — modestly increases risk

Age and Sex

Age is the strongest risk factor for all synucleinopathies. Men appear to be at higher risk for DLB and Parkinson's disease, although the gap narrows in later life and may be partly explained by underdiagnosis in women.

Environmental Exposures

Some pesticides and heavy metals have been linked to Parkinson's disease and may by extension contribute to Lewy body dementia. Head injury and chronic occupational exposures are areas of ongoing research. None of these factors alone reliably predict who will develop the disease.

Comorbid Alzheimer's Pathology

Coexisting amyloid and tau pathology is common in autopsy studies of patients with clinical DLB and modifies the clinical course. Greater Alzheimer's burden generally predicts faster decline.

What Does Not Cause It

Lewy body dementia is not caused by stress, personality, family conflict, or "doing too much thinking." It is also not the same as Alzheimer's, vascular dementia, or any psychiatric disorder, although it can be mistaken for any of these.

Medical Complications

Antipsychotic Sensitivity

Severe reactions to antipsychotic medications have been reported in up to half of people with Lewy body dementia in some studies. Reactions include marked worsening of parkinsonism, profound confusion, autonomic instability and, rarely, neuroleptic malignant syndrome, a life-threatening reaction with high fever, rigidity and altered mental status. Older "typical" antipsychotics carry the highest risk. For this reason, specialists approach any antipsychotic use with great caution, and decisions are made by clinicians experienced in Lewy body disease.

Falls and Fractures

Postural instability, orthostatic hypotension, fluctuating attention, and visuospatial problems combine to make falls extremely common. Hip fractures and head injuries are major morbidities and often precipitate sharp decline.

Aspiration Pneumonia

Bradykinesia and bulbar involvement impair swallowing as disease progresses. Aspiration pneumonia is a leading cause of death.

Orthostatic Syncope and Cardiovascular Events

Autonomic failure produces orthostatic hypotension that can lead to syncope, falls, and reduced cerebral perfusion. Conversely, supine hypertension may coexist and complicate management.

Urinary Symptoms and Infections

Detrusor dysfunction predisposes to urinary retention, urinary tract infections, and acute on chronic delirium during infection episodes.

Constipation

Constipation is often severe and may predate motor symptoms by years. Bowel obstruction is a recognized risk in advanced disease.

Depression and Suicide Risk

Depression is common at all stages. The combination of disability awareness, hallucinations, and disordered sleep can be particularly distressing. Suicide risk warrants attention, especially around the time of diagnosis.

Caregiver Strain

Caring for someone with Lewy body dementia is widely regarded as more demanding than caring for someone with Alzheimer's, given the fluctuations, hallucinations, motor needs, sleep disruption, and behavioral symptoms. Caregiver depression, burnout, and physical illness are common and require dedicated support.

Assessment and Diagnosis

Clinical Interview

Diagnosis is fundamentally clinical and rests on careful history-taking. Specific questioning is necessary because patients and families may not spontaneously report key symptoms. Useful questions include:

• Do attention and alertness vary significantly from one part of the day to another?
• Do you see things that others do not see — people, children, animals?
• Do you ever feel that someone is in the room when you know no one is there?
• Do you act out your dreams — talking, shouting, or moving in your sleep?
• Have you fainted or become lightheaded on standing?
• Is constipation long-standing?
• Has your sense of smell decreased?

Cognitive Testing

Tests sensitive to attention and visuospatial function — the Trail Making Test, clock drawing, intersecting pentagons or cube copy, digit span backwards — are particularly informative. Memory deficits in early DLB often show better recognition than free recall, in contrast to typical Alzheimer's.

Neurological Examination

Look for bradykinesia, rigidity (especially symmetric and axial), reduced facial expression, decreased arm swing, stooped posture, and postural instability. Tremor is less common than in idiopathic Parkinson's disease.

Polysomnography

A sleep study with EMG can confirm REM sleep without atonia, the polysomnographic hallmark of REM sleep behavior disorder. This is the most specific biomarker for synucleinopathy in patients presenting with dream enactment.

DaT Scan (Dopamine Transporter Imaging)

DaT-SPECT visualizes presynaptic dopaminergic terminals in the striatum. Reduced uptake supports the diagnosis of DLB or PDD, distinguishing them from Alzheimer's disease, in which DaT uptake is normal. False negatives can occur in early disease.

Cardiac MIBG Scintigraphy

Reduced uptake of MIBG (a noradrenaline analogue) in cardiac sympathetic nerves is highly specific for Lewy body pathology, reflecting widespread peripheral autonomic involvement. Availability varies by region.

MRI

MRI is used primarily to exclude other causes such as strategic strokes, normal pressure hydrocephalus, or significant vascular disease. Relative preservation of the medial temporal lobes, in contrast to Alzheimer's disease, is a supportive feature.

Other Tests

• Standard blood work to exclude reversible contributors
• Skin biopsy with detection of phosphorylated alpha-synuclein, increasingly used in research settings
• Alpha-synuclein seed amplification assays in CSF, emerging as a sensitive and specific biomarker
• Olfactory testing — a useful clinical pointer

Differential Diagnosis

• Alzheimer's disease — distinguishing memory-first vs. attention/visuospatial-first presentations
• Vascular dementia — focal signs, stepwise change, imaging evidence of stroke
• Parkinson's disease without dementia — motor signs without cognitive impairment
• Delirium — abrupt onset, identifiable trigger, broader systemic illness
• Late-onset psychosis or primary psychiatric disorders
• Charles Bonnet syndrome — formed hallucinations in those with severe visual loss, without dementia or psychiatric features
• Progressive supranuclear palsy and corticobasal syndrome (other atypical parkinsonisms)

Treatment Approaches

There is currently no treatment that slows or stops the underlying disease, but many symptoms can be eased. Because people with Lewy body dementia react unusually to several medications, treatment is best coordinated by a neurologist, geriatrician or old-age psychiatrist familiar with the condition.

Medication for Cognition and Hallucinations

Some of the medications used in Alzheimer's disease, particularly the cholinesterase inhibitor class, have trial evidence in Lewy body dementia and may improve attention, alertness and visual hallucinations, sometimes more than in Alzheimer's disease. This reflects the especially large loss of the chemical messenger acetylcholine in this condition. Whether a medication is appropriate, and which one, is a decision for the treating doctor.

Movement Symptoms

Parkinsonian symptoms such as slowness and stiffness may be treated with medications used in Parkinson's disease. Response is often more modest than in Parkinson's disease, and doctors weigh motor benefit against the risk of worsening hallucinations, confusion or sleepiness. Physical therapy is an important part of managing movement and balance.

Managing Hallucinations and Psychosis

If hallucinations are not distressing and the person recognizes them as unreal, no medication may be needed. When they are distressing or disruptive, clinicians typically take a stepwise approach:

• Identify and treat reversible triggers such as infection, dehydration or pain.
• Review the medication list and reduce drugs that can worsen confusion or hallucinations where possible.
• Use environmental strategies: good lighting, less clutter, calm reassurance rather than confrontation.
• Consider dementia medications that may reduce hallucinations.
• Only if necessary, consider very cautious use of specific medications by an experienced specialist, given the risk of severe sensitivity reactions.

REM Sleep Behavior Disorder

Bedroom safety comes first: padded floor space, moving furniture and breakable items away from the bed, and sometimes separate beds for partners. A doctor may also discuss treatments to reduce dream enactment, weighing benefits against effects on balance, alertness and cognition. See REM sleep behavior disorder.

Autonomic Symptoms

• Low blood pressure on standing: rising slowly, adequate fluids and other measures recommended by a doctor; medical treatment may be needed, and high blood pressure when lying down can complicate management.
• Constipation: fluids, fiber, regular toileting and, if needed, treatment advised by a clinician.
• Urinary symptoms: bladder training and scheduled toileting; some bladder medications can worsen confusion, so choices are reviewed carefully.
• Daytime sleepiness: good sleep routines and screening for other sleep disorders such as sleep apnea.

Depression and Anxiety

Depression and anxiety are common and treatable. Psychological approaches such as behavioral activation, cognitive behavioral therapy adapted for older adults, and engagement in meaningful activity can help. Medication is one option a doctor may discuss, taking into account that some medications can worsen confusion or constipation in Lewy body dementia.

Nonpharmacological Care

• Consistent routines, predictable schedules, and uncluttered environments
• Good lighting to reduce visual misperceptions
• Physical therapy for balance, gait, and fall prevention
• Occupational therapy for adaptations at home
• Speech and swallow therapy as needed
• Music therapy and structured cognitive stimulation

Surgical and Procedural Considerations

People with Lewy body dementia have a higher risk of postoperative delirium and confusion, and anesthetic plans should account for this. Sensitivity to several types of sedating and pain-relieving medication is heightened. Surgical teams should be informed of the diagnosis, and elective procedures should be carefully considered against the expected benefit.

Advance Care Planning

Because cognition fluctuates and parkinsonism progresses, planning early is particularly important. Conversations about preferences for hospitalization, antibiotic use for infections, feeding decisions, and end-of-life care benefit from being held while the person can fully participate.

Living With and Caring For Lewy Body Dementia

Day-to-Day Strategies

Daily life with Lewy body dementia is shaped by the unpredictability of fluctuations. Practical strategies include scheduling demanding activities, social visits, and appointments during typically clearer periods of the day; allowing extended time for transitions; and accepting that "off" days are part of the condition rather than something to be argued away. Visual environment matters: good lighting reduces hallucinations and misperceptions, while clutter and shadows can worsen them.

Responding to Hallucinations

• Stay calm and avoid arguing with the experience
• Acknowledge what the person sees without confirming or denying its reality
• Try gentle distraction — turning on lights, changing rooms, suggesting an activity
• Look for triggers — fatigue, infection, medication changes
• Document patterns and share them with the medical team

Sleep Safety

• Remove sharp objects, glass, and breakable items from the bedside
• Consider lowering the mattress to floor level or using bed rails carefully (rails can also pose a risk)
• Use a baby monitor or audio device so partners or caregivers can hear nocturnal events
• Discuss separate sleeping arrangements with partners when safety is a concern

Driving

Lewy body dementia frequently impairs driving safety earlier than people realize, given the combination of attention fluctuations, slowed reactions, parkinsonism, and visuospatial difficulty. Formal driving evaluation through an occupational therapist is appropriate at diagnosis or whenever concerns arise.

Communicating Diagnosis Across the Medical Team

Because antipsychotic sensitivity is so dangerous, the diagnosis should be communicated clearly to every clinician, dentist, surgeon, anesthesiologist, and emergency room — and it should be documented prominently in the medical record. A wallet card or medical alert bracelet can prevent reflexive prescribing of high-risk medications during emergencies.

For Caregivers

Caregiving in Lewy body dementia is demanding and unpredictable. Sustainable support requires education about the disease, practical training in responding to hallucinations and motor difficulties, regular respite, attention to one's own physical and mental health, and connection with others in the same situation. Support groups specific to Lewy body dementia exist through national organizations and offer particular value because the issues are distinct from those of other dementias.

Late-Stage Care

Late-stage Lewy body dementia involves significant motor disability, increased risk of pneumonia and other infections, and progression of cognitive impairment. Palliative care principles guide symptom management, with hospice services appropriate as the trajectory advances. Comfort, dignity, and the company of trusted people remain the priorities.

When to Seek Help

Get Evaluated

Evaluation is appropriate for any combination of cognitive change, new visual hallucinations, dream enactment behaviors, parkinsonian features, recurrent falls, or pronounced fluctuations in alertness in an older adult. Early recognition allows for medication choices that protect against dangerous antipsychotic exposures and for treatments that can meaningfully improve quality of life.

Red Flags Requiring Prompt Attention

• Severe worsening of confusion or rigidity after starting a new medication, especially an antipsychotic
• High fever with stiffness and altered mental status — possible neuroleptic malignant syndrome (emergency)
• Falls with head injury or loss of consciousness
• Acute change in behavior, often signaling infection or delirium
• Severe distress from hallucinations or delusions
• Suicidal thoughts
• Significant caregiver crisis or safety concerns in the home

Where to Start

• Primary care physician for initial workup and referral
• Neurologist with movement disorder or behavioral neurology expertise
• Geriatrician or geriatric psychiatrist for complex behavioral and cognitive issues
• Memory clinic with experience in Lewy body disease
• Sleep specialist for evaluation of suspected RBD or significant sleep disruption
• National Lewy body and dementia charities for education, support groups and research participation

Conclusion

Lewy body dementia is a major cause of neurodegenerative dementia, a synucleinopathy with a distinct clinical signature and important treatment implications. Its hallmarks — fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and parkinsonism — are recognizable when looked for, yet the condition remains widely misdiagnosed. The boundary between DLB and Parkinson's disease dementia is one of timing rather than biology, and the same alpha-synuclein pathology drives both. Recognizing the diagnosis matters because medication choices, prognosis, and family support differ in important ways from those of Alzheimer's disease.

Effective care combines carefully chosen medical treatment for cognition, movement, sleep and autonomic symptoms; thoughtful approaches to hallucinations that avoid high-risk medications; and steady environmental and psychosocial support for the person and their family. Above all, the medication sensitivity that characterizes Lewy body dementia must be communicated across the whole care team to prevent dangerous reactions.

If you or a loved one is experiencing the cluster of features described here, seeking evaluation by a clinician familiar with Lewy body disease is the most important next step. The path ahead is challenging, but informed care, family support, and connection with the Lewy body community can transform the experience. People with this condition can continue to find meaning, joy, and connection across the trajectory of the illness, particularly when their care team understands what they are facing.